Download image:

Stephanie R. Earnshaw

Research Management Scientist, RTI-HS

Stephanie Earnshaw, PhD, applies mathematical modeling, optimization, and decision analysis techniques to industry-related issues and health care problems. She has also extensive experience in survey management. Her areas of specialization include systems optimization and solving resource allocation problems. She has developed innovative mathematical models to determine pricing strategy, budget impact, and cost-effectiveness of new products. Dr. Earnshaw has developed a variety of mathematical models, including Markov models, Monte Carlo simulation models, and other state transition models, to analyse the impact of new medical interventions on disease progression. Dr. Earnshaw also has extensive programming experience and has led programmers in developing user interfaces for health surveys and for several pharmacoeconomic models. Dr. Earnshaw is a member of the Institute for Operations Research and the Management Sciences. She has presented her work at professional conferences and has published in several peer-reviewed journals.


PhD, Industrial Engineering (Operations Research and Management), North Carolina State University; MS, Industrial Engineering (Operations Research), North Carolina State University; BS, Mathematical Science (Operations Research), University of North Carolina at Chapel Hill.

Latest Publications

Barnes, R., Earnshaw, S., Herbrecht, R., Morrissey, O., Slavin, M., Bow, E., McDade, C., et al. (2015). Economic Comparison of an Empirical Versus Diagnostic-Driven Strategy for Treating Invasive Fungal Disease in Immunocompromised Patients. Clinical Therapeutics, 37 (6):1317-1328.
Earnshaw, S.R., Graham, C.N., McDade, C.L., Spears, J.B., & Kessler, C.M. (2015). Factor VIII alloantibody inhibitors: Cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment. Haemophilia, 21 (3):310-319.
Patel, J., Coleman, A., Wilson, M., McDade, C., Carr, S., & Earnshaw , S. (2015). Budgetary impact on a U.S. health plan after adopting umeclidinium/vilanterol (UMEC/VI) for the management of moderate-to-severe COPD, J Manag Care Spec Pharm , 21 (4a):S55-S55.
Ward, M.A., Fang, G., Richards, K.L., Walko, C.M., Earnshaw, S.R., Happe, L.E., et al. (2015). Treatment interruption and regimen change in first-generation versus second-generation tyrosine kinase inhibitors used as first-line therapy for chronic myeloid leukemia. Journal of Health Economics and Outcomes Research (JHEOR), 2 (2):181-191.
Ward, M.A., Fang, G., Richards, K.L., Walko, C.M., Earnshaw, S.R., Happe, L.E., et al. (2015). Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs. Current Medical Research and Opinion, 31 (2):289-297.
View all publications by Stephanie R. Earnshaw (94)


  • Health Economics
  • Pharmacoeconomics
  • Operations Research